| Project/Area Number |
15K10822
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
太田 一郎 奈良県立医科大学, 医学部, 講師 (00326323)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | REG遺伝子 / バイオマーカー / 頭頸部癌 / 癌幹細胞 |
|---|
| Outline of Final Research Achievements |
In this study we demonstrated that Regenerating gene III (REG III) expression was such a marker associated with an improved survival rate for HNSCC patients. Moreover, we found that resveratrol (3,4',5-trihydroxy-trans-stilbene) significantly increased the REG III expression in HNSCC cells, and significantly inhibited cell growth, enhanced chemo- and radio-sensitivity, and blocked cancer invasion of HNSCC cells in vitro. We found that resveratrol certainly increased the mRNA level of REG III in vivo with our in vitro observation previously. Moreover, REG III augmented the anti-tumor effect of radiation or cisplatin in vivo, and resveratrol sensitized HNSCC to irradiation and cisplatin in vivo. These data suggested that resveratrol increases the efficacy of cisplatin and irradiation through REG III expression pathway, resulting in decreased tumor growth in treating HNSCC in vivo.
|
